CO2 Energy Transition Corp.
CO2 Energy Transition Corp. NOEMR Peers
See (NOEMR) competitors and their performances in Stock Market.
Peer Comparison Table: Financial - Conglomerates Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NOEMR | $0.17 | +4.12% | 1.7M | N/A | N/A | N/A |
| TPGXL | $25.92 | +0.47% | 19.6B | N/A | N/A | +3.10% |
| VOYA-PB | $24.40 | -0.85% | 7.1B | 2.92 | $8.44 | +2.46% |
| VOYA | $71.86 | -1.45% | 7.1B | 13.69 | $5.35 | +2.46% |
| BIPH | $16.45 | -0.72% | 6B | N/A | N/A | +9.44% |
| PACS | $12.69 | -1.17% | 2B | 20.98 | $0.61 | N/A |
| MSDL | $19.16 | +0.31% | 1.7B | 8.72 | $2.20 | +11.51% |
| RILYM | $25.11 | +0.00% | 753M | N/A | N/A | +6.35% |
| BEAGU | $10.68 | +0.66% | 614.3M | N/A | N/A | N/A |
| RILYO | $25.13 | -0.02% | 573.5M | N/A | N/A | N/A |
Stock Comparison
NOEMR vs TPGXL Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, TPGXL has a market cap of 19.6B. Regarding current trading prices, NOEMR is priced at $0.17, while TPGXL trades at $25.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas TPGXL's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to TPGXL's ROE of +0.04%. Regarding short-term risk, NOEMR is more volatile compared to TPGXL. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs VOYA-PB Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, VOYA-PB has a market cap of 7.1B. Regarding current trading prices, NOEMR is priced at $0.17, while VOYA-PB trades at $24.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas VOYA-PB's P/E ratio is 2.92. In terms of profitability, NOEMR's ROE is +0.01%, compared to VOYA-PB's ROE of +0.13%. Regarding short-term risk, NOEMR is more volatile compared to VOYA-PB. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs VOYA Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, VOYA has a market cap of 7.1B. Regarding current trading prices, NOEMR is priced at $0.17, while VOYA trades at $71.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas VOYA's P/E ratio is 13.69. In terms of profitability, NOEMR's ROE is +0.01%, compared to VOYA's ROE of +0.13%. Regarding short-term risk, NOEMR is more volatile compared to VOYA. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs BIPH Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, BIPH has a market cap of 6B. Regarding current trading prices, NOEMR is priced at $0.17, while BIPH trades at $16.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas BIPH's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to BIPH's ROE of -0.01%. Regarding short-term risk, NOEMR is more volatile compared to BIPH. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs PACS Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, PACS has a market cap of 2B. Regarding current trading prices, NOEMR is priced at $0.17, while PACS trades at $12.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas PACS's P/E ratio is 20.98. In terms of profitability, NOEMR's ROE is +0.01%, compared to PACS's ROE of +0.11%. Regarding short-term risk, NOEMR is less volatile compared to PACS. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs MSDL Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, MSDL has a market cap of 1.7B. Regarding current trading prices, NOEMR is priced at $0.17, while MSDL trades at $19.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas MSDL's P/E ratio is 8.72. In terms of profitability, NOEMR's ROE is +0.01%, compared to MSDL's ROE of +0.11%. Regarding short-term risk, NOEMR is more volatile compared to MSDL. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILYM Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILYM has a market cap of 753M. Regarding current trading prices, NOEMR is priced at $0.17, while RILYM trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILYM's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILYM's ROE of +17.01%. Regarding short-term risk, NOEMR is more volatile compared to RILYM. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs BEAGU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, BEAGU has a market cap of 614.3M. Regarding current trading prices, NOEMR is priced at $0.17, while BEAGU trades at $10.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas BEAGU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to BEAGU's ROE of +0.07%. Regarding short-term risk, NOEMR is more volatile compared to BEAGU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILYO Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILYO has a market cap of 573.5M. Regarding current trading prices, NOEMR is priced at $0.17, while RILYO trades at $25.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILYO's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILYO's ROE of +17.01%. Regarding short-term risk, NOEMR is more volatile compared to RILYO. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs TREE Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, TREE has a market cap of 551.2M. Regarding current trading prices, NOEMR is priced at $0.17, while TREE trades at $39.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas TREE's P/E ratio is -9.84. In terms of profitability, NOEMR's ROE is +0.01%, compared to TREE's ROE of -0.49%. Regarding short-term risk, NOEMR is less volatile compared to TREE. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs ANSCU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, ANSCU has a market cap of 461.8M. Regarding current trading prices, NOEMR is priced at $0.17, while ANSCU trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas ANSCU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to ANSCU's ROE of +0.02%. Regarding short-term risk, NOEMR is more volatile compared to ANSCU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs BACQU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, BACQU has a market cap of 357.5M. Regarding current trading prices, NOEMR is priced at $0.17, while BACQU trades at $10.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas BACQU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to BACQU's ROE of -0.60%. Regarding short-term risk, NOEMR is more volatile compared to BACQU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs POLEU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, POLEU has a market cap of 339.2M. Regarding current trading prices, NOEMR is priced at $0.17, while POLEU trades at $10.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas POLEU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to POLEU's ROE of +0.04%. Regarding short-term risk, NOEMR is more volatile compared to POLEU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs DRDBU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, DRDBU has a market cap of 324.1M. Regarding current trading prices, NOEMR is priced at $0.17, while DRDBU trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas DRDBU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to DRDBU's ROE of +0.00%. Regarding short-term risk, NOEMR is more volatile compared to DRDBU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs HVIIU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, HVIIU has a market cap of 274.3M. Regarding current trading prices, NOEMR is priced at $0.17, while HVIIU trades at $10.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas HVIIU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to HVIIU's ROE of -0.20%. Regarding short-term risk, NOEMR is more volatile compared to HVIIU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs HVII Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, HVII has a market cap of 264.1M. Regarding current trading prices, NOEMR is priced at $0.17, while HVII trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas HVII's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to HVII's ROE of -0.20%. Regarding short-term risk, NOEMR is more volatile compared to HVII. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs PLMKU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, PLMKU has a market cap of 258.1M. Regarding current trading prices, NOEMR is priced at $0.17, while PLMKU trades at $10.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas PLMKU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to PLMKU's ROE of +0.03%. Regarding short-term risk, NOEMR is less volatile compared to PLMKU. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs NTWOU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, NTWOU has a market cap of 253.5M. Regarding current trading prices, NOEMR is priced at $0.17, while NTWOU trades at $10.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas NTWOU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to NTWOU's ROE of +0.03%. Regarding short-term risk, NOEMR is more volatile compared to NTWOU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs FACTU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, FACTU has a market cap of 253.1M. Regarding current trading prices, NOEMR is priced at $0.17, while FACTU trades at $10.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas FACTU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to FACTU's ROE of +0.17%. Regarding short-term risk, NOEMR is more volatile compared to FACTU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs PLMK Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, PLMK has a market cap of 249M. Regarding current trading prices, NOEMR is priced at $0.17, while PLMK trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas PLMK's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to PLMK's ROE of +0.03%. Regarding short-term risk, NOEMR is more volatile compared to PLMK. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs DMAAU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, DMAAU has a market cap of 239.4M. Regarding current trading prices, NOEMR is priced at $0.17, while DMAAU trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas DMAAU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to DMAAU's ROE of +0.02%. Regarding short-term risk, NOEMR is more volatile compared to DMAAU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs DRDB Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, DRDB has a market cap of 236M. Regarding current trading prices, NOEMR is priced at $0.17, while DRDB trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas DRDB's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to DRDB's ROE of +0.00%. Regarding short-term risk, NOEMR is more volatile compared to DRDB. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs ACOG Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, ACOG has a market cap of 170.4M. Regarding current trading prices, NOEMR is priced at $0.17, while ACOG trades at $10.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas ACOG's P/E ratio is -8.57. In terms of profitability, NOEMR's ROE is +0.01%, compared to ACOG's ROE of -0.49%. Regarding short-term risk, NOEMR is less volatile compared to ACOG. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs TAVIU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, TAVIU has a market cap of 165.8M. Regarding current trading prices, NOEMR is priced at $0.17, while TAVIU trades at $10.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas TAVIU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to TAVIU's ROE of +2.05%. Regarding short-term risk, NOEMR is more volatile compared to TAVIU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RANG Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RANG has a market cap of 164.4M. Regarding current trading prices, NOEMR is priced at $0.17, while RANG trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RANG's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to RANG's ROE of +0.02%. Regarding short-term risk, NOEMR is less volatile compared to RANG. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs SVCCU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, SVCCU has a market cap of 159.7M. Regarding current trading prices, NOEMR is priced at $0.17, while SVCCU trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas SVCCU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to SVCCU's ROE of +0.02%. Regarding short-term risk, NOEMR is more volatile compared to SVCCU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs BSIIU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, BSIIU has a market cap of 152.8M. Regarding current trading prices, NOEMR is priced at $0.17, while BSIIU trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas BSIIU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to BSIIU's ROE of +0.02%. Regarding short-term risk, NOEMR is less volatile compared to BSIIU. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILYL Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILYL has a market cap of 150.7M. Regarding current trading prices, NOEMR is priced at $0.17, while RILYL trades at $4.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILYL's P/E ratio is 0.82. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILYL's ROE of +4.72%. Regarding short-term risk, NOEMR is less volatile compared to RILYL. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILYP Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILYP has a market cap of 140.3M. Regarding current trading prices, NOEMR is priced at $0.17, while RILYP trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILYP's P/E ratio is 0.77. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILYP's ROE of +4.72%. Regarding short-term risk, NOEMR is less volatile compared to RILYP. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILY Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILY has a market cap of 135.9M. Regarding current trading prices, NOEMR is priced at $0.17, while RILY trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILY's P/E ratio is -0.19. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILY's ROE of +4.72%. Regarding short-term risk, NOEMR is less volatile compared to RILY. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILYT Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILYT has a market cap of 127.3M. Regarding current trading prices, NOEMR is priced at $0.17, while RILYT trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILYT's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILYT's ROE of +4.72%. Regarding short-term risk, NOEMR is less volatile compared to RILYT. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILYN Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILYN has a market cap of 119.1M. Regarding current trading prices, NOEMR is priced at $0.17, while RILYN trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILYN's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILYN's ROE of +4.72%. Regarding short-term risk, NOEMR is less volatile compared to RILYN. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILYG Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILYG has a market cap of 117.5M. Regarding current trading prices, NOEMR is priced at $0.17, while RILYG trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILYG's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILYG's ROE of +4.72%. Regarding short-term risk, NOEMR is more volatile compared to RILYG. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs SPHA Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, SPHA has a market cap of 111.7M. Regarding current trading prices, NOEMR is priced at $0.17, while SPHA trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas SPHA's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to SPHA's ROE of N/A. Regarding short-term risk, NOEMR is more volatile compared to SPHA. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILYK Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILYK has a market cap of 105.6M. Regarding current trading prices, NOEMR is priced at $0.17, while RILYK trades at $22.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILYK's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILYK's ROE of +4.72%. Regarding short-term risk, NOEMR is less volatile compared to RILYK. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs NOEM Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, NOEM has a market cap of 96.6M. Regarding current trading prices, NOEMR is priced at $0.17, while NOEM trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas NOEM's P/E ratio is 252.00. In terms of profitability, NOEMR's ROE is +0.01%, compared to NOEM's ROE of +0.01%. Regarding short-term risk, NOEMR is more volatile compared to NOEM. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs DTSQ Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, DTSQ has a market cap of 92.5M. Regarding current trading prices, NOEMR is priced at $0.17, while DTSQ trades at $10.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas DTSQ's P/E ratio is 49.48. In terms of profitability, NOEMR's ROE is +0.01%, compared to DTSQ's ROE of +0.11%. Regarding short-term risk, NOEMR is more volatile compared to DTSQ. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RMI Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RMI has a market cap of 91.2M. Regarding current trading prices, NOEMR is priced at $0.17, while RMI trades at $14.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RMI's P/E ratio is 16.64. In terms of profitability, NOEMR's ROE is +0.01%, compared to RMI's ROE of +0.05%. Regarding short-term risk, NOEMR is more volatile compared to RMI. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs FLDD Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, FLDD has a market cap of 85.6M. Regarding current trading prices, NOEMR is priced at $0.17, while FLDD trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas FLDD's P/E ratio is -75.13. In terms of profitability, NOEMR's ROE is +0.01%, compared to FLDD's ROE of N/A. Regarding short-term risk, NOEMR is less volatile compared to FLDD. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs CAPNU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, CAPNU has a market cap of 81.5M. Regarding current trading prices, NOEMR is priced at $0.17, while CAPNU trades at $10.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas CAPNU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to CAPNU's ROE of +0.03%. Regarding short-term risk, NOEMR is more volatile compared to CAPNU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs YHNA Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, YHNA has a market cap of 80.1M. Regarding current trading prices, NOEMR is priced at $0.17, while YHNA trades at $10.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas YHNA's P/E ratio is 41.36. In terms of profitability, NOEMR's ROE is +0.01%, compared to YHNA's ROE of +0.04%. Regarding short-term risk, NOEMR is more volatile compared to YHNA. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs BAYAU Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, BAYAU has a market cap of 58.3M. Regarding current trading prices, NOEMR is priced at $0.17, while BAYAU trades at $10.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas BAYAU's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to BAYAU's ROE of +0.04%. Regarding short-term risk, NOEMR is more volatile compared to BAYAU. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs COOTW Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, COOTW has a market cap of 21.6M. Regarding current trading prices, NOEMR is priced at $0.17, while COOTW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas COOTW's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to COOTW's ROE of +0.11%. Regarding short-term risk, NOEMR is less volatile compared to COOTW. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs DRDBW Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, DRDBW has a market cap of 12.1M. Regarding current trading prices, NOEMR is priced at $0.17, while DRDBW trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas DRDBW's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to DRDBW's ROE of +0.02%. Regarding short-term risk, NOEMR is more volatile compared to DRDBW. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs BSLKW Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, BSLKW has a market cap of 6.5M. Regarding current trading prices, NOEMR is priced at $0.17, while BSLKW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas BSLKW's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to BSLKW's ROE of +0.56%. Regarding short-term risk, NOEMR is less volatile compared to BSLKW. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs MLACR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, MLACR has a market cap of 5.4M. Regarding current trading prices, NOEMR is priced at $0.17, while MLACR trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas MLACR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to MLACR's ROE of +0.02%. Regarding short-term risk, NOEMR is more volatile compared to MLACR. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs HVIIR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, HVIIR has a market cap of 5.2M. Regarding current trading prices, NOEMR is priced at $0.17, while HVIIR trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas HVIIR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to HVIIR's ROE of -0.20%. Regarding short-term risk, NOEMR is more volatile compared to HVIIR. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs PLMKW Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, PLMKW has a market cap of 4.4M. Regarding current trading prices, NOEMR is priced at $0.17, while PLMKW trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas PLMKW's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to PLMKW's ROE of N/A. Regarding short-term risk, NOEMR is less volatile compared to PLMKW. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs APLMW Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, APLMW has a market cap of 4.1M. Regarding current trading prices, NOEMR is priced at $0.17, while APLMW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas APLMW's P/E ratio is -0.01. In terms of profitability, NOEMR's ROE is +0.01%, compared to APLMW's ROE of -2.11%. Regarding short-term risk, NOEMR is less volatile compared to APLMW. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RANGR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RANGR has a market cap of 4M. Regarding current trading prices, NOEMR is priced at $0.17, while RANGR trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RANGR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to RANGR's ROE of +0.02%. Regarding short-term risk, NOEMR is more volatile compared to RANGR. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs TENKR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, TENKR has a market cap of 3.2M. Regarding current trading prices, NOEMR is priced at $0.17, while TENKR trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas TENKR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to TENKR's ROE of -0.32%. Regarding short-term risk, NOEMR is less volatile compared to TENKR. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs YHNAR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, YHNAR has a market cap of 1.4M. Regarding current trading prices, NOEMR is priced at $0.17, while YHNAR trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas YHNAR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to YHNAR's ROE of N/A. Regarding short-term risk, NOEMR is less volatile compared to YHNAR. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs EURKR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, EURKR has a market cap of 1.4M. Regarding current trading prices, NOEMR is priced at $0.17, while EURKR trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas EURKR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to EURKR's ROE of N/A. Regarding short-term risk, NOEMR is less volatile compared to EURKR. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs DTSQR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, DTSQR has a market cap of 1.2M. Regarding current trading prices, NOEMR is priced at $0.17, while DTSQR trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas DTSQR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to DTSQR's ROE of N/A. Regarding short-term risk, NOEMR is more volatile compared to DTSQR. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs FSHPR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, FSHPR has a market cap of 1.2M. Regarding current trading prices, NOEMR is priced at $0.17, while FSHPR trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas FSHPR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to FSHPR's ROE of N/A. Regarding short-term risk, NOEMR is more volatile compared to FSHPR. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs CAPNR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, CAPNR has a market cap of 1.1M. Regarding current trading prices, NOEMR is priced at $0.17, while CAPNR trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas CAPNR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to CAPNR's ROE of N/A. Regarding short-term risk, NOEMR is less volatile compared to CAPNR. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs ATMCR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, ATMCR has a market cap of 819.1K. Regarding current trading prices, NOEMR is priced at $0.17, while ATMCR trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas ATMCR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to ATMCR's ROE of +0.04%. Regarding short-term risk, NOEMR is more volatile compared to ATMCR. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs BRACR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, BRACR has a market cap of 536.9K. Regarding current trading prices, NOEMR is priced at $0.17, while BRACR trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas BRACR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to BRACR's ROE of -0.14%. Regarding short-term risk, NOEMR is less volatile compared to BRACR. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs EMCGR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, EMCGR has a market cap of 516.2K. Regarding current trading prices, NOEMR is priced at $0.17, while EMCGR trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas EMCGR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to EMCGR's ROE of +0.04%. Regarding short-term risk, NOEMR is more volatile compared to EMCGR. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs SPHAR Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, SPHAR has a market cap of 0. Regarding current trading prices, NOEMR is priced at $0.17, while SPHAR trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas SPHAR's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to SPHAR's ROE of N/A. Regarding short-term risk, NOEMR is less volatile compared to SPHAR. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILYH Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILYH has a market cap of 0. Regarding current trading prices, NOEMR is priced at $0.17, while RILYH trades at $25.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILYH's P/E ratio is 43.70. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILYH's ROE of +4.72%. Regarding short-term risk, NOEMR is more volatile compared to RILYH. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs BIPJ Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, BIPJ has a market cap of 0. Regarding current trading prices, NOEMR is priced at $0.17, while BIPJ trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas BIPJ's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to BIPJ's ROE of N/A. Regarding short-term risk, NOEMR is more volatile compared to BIPJ. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs LCAAW Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, LCAAW has a market cap of 0. Regarding current trading prices, NOEMR is priced at $0.17, while LCAAW trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas LCAAW's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to LCAAW's ROE of +0.10%. Regarding short-term risk, NOEMR is less volatile compared to LCAAW. This indicates potentially lower risk in terms of short-term price fluctuations for NOEMR.
NOEMR vs RILYI Comparison
NOEMR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOEMR stands at 1.7M. In comparison, RILYI has a market cap of 0. Regarding current trading prices, NOEMR is priced at $0.17, while RILYI trades at $25.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOEMR currently has a P/E ratio of N/A, whereas RILYI's P/E ratio is N/A. In terms of profitability, NOEMR's ROE is +0.01%, compared to RILYI's ROE of +2.01%. Regarding short-term risk, NOEMR is more volatile compared to RILYI. This indicates potentially higher risk in terms of short-term price fluctuations for NOEMR.